Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, S. N. | - |
dc.contributor.author | Kim, H. J. | - |
dc.contributor.author | Kim, K. H. | - |
dc.contributor.author | Han, S. -J. | - |
dc.contributor.author | Ahn, I. M. | - |
dc.contributor.author | Ahn, H. S. | - |
dc.date.accessioned | 2021-09-03T11:17:47Z | - |
dc.date.available | 2021-09-03T11:17:47Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/85009 | - |
dc.description.abstract | Background The low incidence of Mycobacterium tuberculosis infection and lack of adequate controls have prevented researchers from estimating tuberculosis (TB) risk in inflammatory bowel disease (IBD) patients. Aim To evaluate the risk of incident TB among IBD patients. Methods Using the 2011-2013 data of the South Korean National Health Insurance (NHI) system, we calculated the incidence rates (IRs), standardised incidence ratio (SIR) and number needed to screen (NNS) for incident TB in IBD patients compared to the general population in terms of subtype, age, gender and IBD medications. Results The IR, SIR and NNS for TB in IBD patients were 223.9/100 000 person-years, 2.64 (2.30-3.01) and 446.6 (392.8-517.6), respectively. The TB IR in Crohn's disease (CD) patients was significantly higher than that in ulcerative colitis (UC) patients (340.1/100 000 person-years vs. 165.5/100 000 person-years, respectively; P < 0.001). The SIR and NNS for TB among CD patients were 4.00 (3.59-4.45) and 604.2 (506.1-749.6), respectively; those among UC patients were 1.95 (1.66-2.27) and 294.0 (246.9-363.4). The TB IRs in IBD patients did not differ significantly by age or gender (Ptrend = 0.505 and P = 0.861, respectively). The TB IRs among IBD patients prescribed 5-ASA, corticosteroids, immunomodulators and anti-TNF-alpha were 143.5, 208.5, 284.6 and 554.1 per 100 000 person-years, respectively. Among IBD patients treated using anti-TNF-alpha, the TB IR was significantly higher than that among all IBD patients (P < 0.001); the SIR and NNS for TB were 6.53 (5.99-7.09) and 180.5 (144.6-240.1) respectively. Conclusion Clinicians should be aware of the increased risk of active tuberculosis in patients with IBD who are receiving anti-TNF-alpha therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | INFLIXIMAB MAINTENANCE THERAPY | - |
dc.subject | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject | CROHNS-DISEASE | - |
dc.subject | ULCERATIVE-COLITIS | - |
dc.subject | ANTI-TNF | - |
dc.subject | ACTIVE TUBERCULOSIS | - |
dc.subject | NATURAL-HISTORY | - |
dc.subject | REACTIVATION | - |
dc.subject | PREDICTORS | - |
dc.subject | ADALIMUMAB | - |
dc.title | Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, H. S. | - |
dc.identifier.doi | 10.1111/apt.13851 | - |
dc.identifier.scopusid | 2-s2.0-84998537712 | - |
dc.identifier.wosid | 000389441900005 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.45, no.2, pp.253 - 263 | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 253 | - |
dc.citation.endPage | 263 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INFLIXIMAB MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | ANTI-TNF | - |
dc.subject.keywordPlus | ACTIVE TUBERCULOSIS | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | REACTIVATION | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.